What happens at Mounjaro week 6?

Where does week 6 typically fall in the Mounjaro titration schedule?

Tirzepatide (the medicine in Mounjaro) is prescribed at 2.5 mg for the first four weeks. That opening dose is about helping your body settle in, not about maximum effect. Most prescribers then move patients to 5 mg at week 5, which means week 6 is your second injection at the higher dose.

Some people stay at 2.5 mg a little longer if side effects have been notable, that decision belongs to your prescriber, not to a general timeline. The week-by-week Mounjaro guide covers how each phase of the titration unfolds and what tends to shift at each step.

If you want to look back at what the week before this felt like for most patients, the Mounjaro week 5 overview explains what that transition week typically brings. And for context on where you're heading, the week 7 picture is worth reading once you've got week 6 behind you.

The practical upshot: week 6 is rarely the same for any two people, but for most it sits at the beginning of the 5 mg phase, a point where the medicine starts doing more of the heavy lifting on appetite.

What side effects are most common at week 6, and are they improving yet?

The gastrointestinal effects of Mounjaro (nausea, constipation, diarrhoea, indigestion, and feeling full very quickly) are typically most pronounced in the first two to four weeks of a new dose. By week 6, many people find they've noticeably settled from the 2.5 mg phase, though the step to 5 mg can bring a milder second wave of GI symptoms.

The NHS medicines information for tirzepatide confirms this GI-led profile and notes that these effects are generally temporary, with most patients finding they reduce over time as the body adapts. NHS guidance on tirzepatide lists what to expect and which symptoms warrant contacting a prescriber promptly.

One symptom that should not be dismissed at any stage: severe, persistent abdominal pain that radiates to the back, with or without vomiting. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines. If that symptom pattern appears, seek urgent medical attention rather than waiting to see whether it passes.

Day-to-day management tip passed on by our prescribers: keeping the pen stored correctly matters throughout treatment. Keeping it in the fridge door (2–8 °C) between injections and checking it isn't frozen or exposed to direct light takes thirty seconds and avoids the issue of a compromised dose at a moment you'd rather not troubleshoot.

How much weight loss should someone expect to have seen by week 6?

There is no single right answer, which is frustrating but honest. Factors including starting weight, current dose, dietary changes, activity levels, and individual biology all shape the number on the scale at six weeks.

What the SURMOUNT-1 clinical trial showed (involving thousands of adults over 72 weeks at the highest dose) is that average weight loss of around 20–21% of body weight is achievable over the full treatment period. The published SURMOUNT-1 trial in the New England Journal of Medicine sets out those results in full. At six weeks you are still very early in that arc.

Clinically, a few kilograms of loss by week 6 is typical for many patients, but some see more and some see less. The trajectory matters more than any single weigh-in. If the scale hasn't shifted at all by this stage, it is worth mentioning to your prescriber, not because something is necessarily wrong, but because they can review the full picture. You can read about what Mounjaro weight loss looks like by eight weeks for a slightly longer-range perspective.

For cost context if you're weighing up whether to continue, the Mounjaro pricing guide explains what private treatment involves and what a legitimate prescription includes.

What should you do if week 6 isn't going as expected?

Side effects worse than expected, no appetite change, no weight movement, or uncertainty about your next dose: all of these are conversations for your prescriber, not decisions to make alone. Adjusting your own dose timing, skipping injections, or switching between pen strengths without clinical sign-off can affect both safety and results.

The tirzepatide overview and the broader Mounjaro information page cover the medicine's mechanism and licensed use in more detail if you want clinical context for what's happening. For questions about interactions (for example, if you take other medicines regularly) the Mounjaro and gabapentin page shows the kind of interaction review a prescriber carries out; the same applies to any regular medication.

If you haven't yet started treatment and are researching this stage in advance, the first week on Mounjaro guide gives useful context on what the very beginning looks like before week 6 arrives. And if you have questions that don't fit anywhere else, our FAQs cover the questions our prescribers hear most often. The right support at week 6 is a prescriber review, not a forum post.